Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
Legacy of Health Information Stewardship
The legacy of general health and science information dissemination has long served as a foundation for public understanding of complex medical topics. Within this tradition, platforms dedicated to developmental medicine and environmental health have maintained rigorous documentation practices, bridging clinical knowledge with patient advocacy. This heritage of careful information stewardship provides a natural framework for examining emerging pharmaceutical safety concerns. As the scope of public health inquiry has expanded, the same methodological rigor applied to pediatric neurology now extends to broader pharmacological surveillance. The transition from general health education to specific drug safety analysis represents a logical progression in evidence-based communication. Within this continuum, the relationship between bisphosphonate therapy and adverse outcomes has become a subject of focused investigation.
From General Education to Specific Drug Safety
Building on this tradition of rigorous health information dissemination, we now turn to a focused analysis of Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect of bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously or following dental procedures.
Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw
ONJ typically presents as exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental surgery. The condition is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease or other jaw pathologies. Multiscale characterization of jawbone tissue, including assessments of tissue mineral density distribution and nanoindentation properties, provides comprehensive information that can help understand jawbone-specific responses to bisphosphonate-related osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially predisposing it to necrosis.
Fosamax Pharmacology and Reported Adverse Effects
Fosamax is a nitrogen-containing bisphosphonate that binds to hydroxyapatite in bone, inhibiting osteoclast activity and reducing bone turnover. While this effect is beneficial for osteoporosis, it can lead to oversuppression of bone remodeling, particularly in the jaw, which has high turnover rates. The prescribing information for Fosamax explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similarly, the label for Fosamax Plus D notes that ONJ can occur spontaneously and is generally associated with invasive dental procedures, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include cancer diagnosis, concomitant therapies such as chemotherapy or corticosteroids, poor oral hygiene, and pre-existing dental disease. The risk of ONJ may increase with longer duration of bisphosphonate exposure.
Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw
The pathogenesis of bisphosphonate-related ONJ involves multiple mechanisms. Bisphosphonates suppress osteoclast-mediated bone resorption, which impairs the normal turnover and repair of jawbone, especially after trauma such as tooth extraction. This leads to accumulation of microdamage and reduced vascularity, promoting necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, further compromising blood supply to the jaw. The multiscale characterization of jawbone in animal models treated with alendronate (the active ingredient in Fosamax) shows alterations in tissue mineral density and mechanical properties, suggesting that the drug directly affects jawbone structure and resilience (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes may increase susceptibility to infection and delayed healing, culminating in ONJ.
Adequacy of Warnings Regarding Fosamax and Osteonecrosis of the Jaw
Causation-Related Considerations for Affected Patients
Establishing causation between Fosamax and ONJ requires careful evaluation of temporal relationship, exclusion of other causes, and biological plausibility. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, and a subset have recurrence of symptoms when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal role. However, ONJ can also occur spontaneously in patients not taking bisphosphonates, and risk factors such as dental disease, cancer, or corticosteroid use may confound the association. In placebo-controlled clinical studies of Fosamax, the percentages of patients with upper gastrointestinal symptoms were similar in the Fosamax and placebo groups, but ONJ was not systematically assessed in these trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Thus, while the evidence supports a causal link, individual patient factors must be considered.
Timeline Between Exposure and Documented Harm
The onset of ONJ after starting Fosamax can range from one day to several months, but the condition is more commonly reported after longer-term use, particularly beyond three years. The risk of ONJ may increase with duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, symptoms often resolve after discontinuation, but delayed healing and recurrence are possible. The label recommends discontinuing Fosamax if severe symptoms develop, and for those requiring invasive dental procedures, stopping treatment may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This timeline underscores the importance of dental evaluation before and during Fosamax therapy.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?
The prescribing information for Fosamax explicitly states that osteonecrosis of the jaw (ONJ) has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Mechanistic studies show that bisphosphonates suppress bone remodeling and may have anti-angiogenic effects, leading to microdamage and reduced blood supply in the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The temporal relationship and recurrence upon rechallenge further support causation.
How long after starting Fosamax can osteonecrosis of the jaw occur?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.